Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies - DOS47. DOS47 is a naturally occurring enzyme that coverts urea into ammonia and generates an alkaline media at the site of action. This effectively combats the acidic tumor microenvironment that is known to suppresses the immune system. Helix’s product development initiatives include its lead candidate L-DOS47 which is currently in clinical studies for lung and pancreatic cancer.
TRACON Pharmaceuticals, Helix BioPharma, Tetra Bio-Pharma and MediPharm Labs are among the standouts presenting at the investor-focused event